Pharmacokinetic evaluation of piperacillin-tazobactam

  title={Pharmacokinetic evaluation of piperacillin-tazobactam},
  author={Yoshiro Hayashi and Jason Alexander Roberts and David L. Paterson and Jeffrey Lipman},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  pages={1017 - 1031}
Importance of the field: Piperacillin-tazobactam is a frequently prescribed intravenous antibiotic for moderate to severe infections used in hospital settings because of its broad activity against many pathogenic bacteria including Pseudomonas aeruginosa. However, its pharmacokinetics (PK) can be significantly altered in a variety of states. Areas covered in this review: This article provides a comprehensive and critical review of the PK of piperacillin-tazobactam in different patient… 

Targeted benefits of prolonged-infusion piperacillin-tazobactam in an in vitro infection model of Pseudomonas aeruginosa

Abstract Given the inconsistent clinical findings, our goal was to characterize the pharmacodynamics (PDs) of prolonged-infusion piperacillin-tazobactam (TZP) in an in vitro pharmacodynamic model of

Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses

Simulations showed that continuous or extended infusion methods performed better than intermittent administration to achieve appropriate pharmacodynamic targets, and pharmacokinetic elements for piperacillin-tazobactam in an intensive care unit setting were synthesized.

Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute Infections

Both piperacillin and tazobactam clearances were significantly influenced by creatinine clearance, and the PK profiles of TZP at a steady-state in Korean patients with acute infections were well described by a two-compartment model with first-order elimination.

Re-evaluating the role of piperacillin-tazobactam in the treatment of hospital-acquired infections

The objectives were to determine the minimum inhibitory concentrations (MICs) of piperacillin-tazobactam against blood culture isolates over a two-year period, and to compare the MICs with isolates from the same site upon the South African launch of p Piperacillin, to evaluate and contextualise contemporary dosing strategies.

Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy

For most critically ill patients, individualized p Piperacillin regimens delivering a target serum piperacillin concentration is achievable, and a linear clearance model with creatinine clearance and weight as covariates for drug clearance and volume of distribution best described the observed data.

Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial Infections

It is suggested that extended infusion of TZP is the most effective method of administration for patients with nosocomial infections and due to the hyperclearance nature of the hospitalized patient populations studied, more intensive TzP dosing regimens may be needed to maximize fT>MIC in certain hospitalized populations.

Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients

Pulmonary piperacillin and tazobactam concentrations were unpredictable and negatively correlated with pulmonary permeability, which may mean current p Piperacillin–tazobactsam regimens may be insufficient to treat pneumonia caused by piperACillin–TazobACTam–susceptible organisms in some critically ill patients.

Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study.

In a population of haematological malignancy patients with neutropenia, renal function and ALP influenced the PK of piperacillin/tazobactam, especially in the case of augmented renal CL and/or low-range bacterial susceptibility.

Evaluating Outcomes Associated with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Qualitative Systematic Review

The limited evidence available does not firmly support widespread adoption of administering piperacillin/tazobactam as prolonged intermittent or continuous infusions to improve clinical outcomes despite the achievement of higher pharmacodynamic targets in simulated studies.

Population Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: an ASAP ECMO Study

Piperacillin and tazobactam were both adequately described by two-compartment models, with body mass index, creatinine clearance, and RRT as significant predictors of PK.



Pharmacokinetic characteristics of piperacillin/tazobactam

Findings show that piperacillin/tazobactam is a truly synergistic combination which can be expected to be effective in treating a wide variety of infections in the clinical setting.

Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.

Intermittent infusion and continuous infusion of piperacillin and tazobactam provided sufficient drug exposure to treat those pathogens commonly implicated in intra-abdominal infections.

Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection

It has been shown here that the recommended dosage regimen for administration of PPR-TZB must be high in major-burn patients, i.e., 4 g/0.5 g every 6 h, and evidence was found in burn patients, in contrast to healthy subjects, of a marked increase in apparent volumes of distribution, in such a way that the apparent elimination half-lives of the combination were notably prolonged.

Serum Piperacillin/Tazobactam Pharmacokinetics in a Morbidly Obese Individual

Pathogens with elevated MICs may require altered dosing schemes with piperacillin/tazobactam, and future studies are warranted to assess increased dosages, more frequent dosing intervals, or continuous infusion dosed schemes for obese individuals with serious infections.

Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections: Results of a Double-Blind, Randomized Comparative Phase III Trial

The results of this trial suggest that ertapenem may be a useful option that could eliminate the need for combination and/or multidosed antibiotic regimens for the empiric treatment of intraabdominal infections.

Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam.

High-dose P/T regimens with extended interval were well tolerated and provide adequate dynamic exposure for a variety of susceptible pathogens.

Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin.

The pharmacokinetics of tazobactam administered intravenously alone were compared with the pharmacokinetically coadministered with piperacillin, and the penetration into an inflammatory exudate in six healthy males was studied.

Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children

Data combined with the known in vitro susceptibilities of a broad range of pediatric bacterial pathogens indicate that a dose of 100 mg of piperacillin and 12.5 of mg tazobactam per kg of body weight administered as a fixed-dose combination every 6 to 8 h would be appropriate to initiate clinical efficacy studies in infants and children for the treatment of systemic infections arising outside of the central nervous system.